Comparator: naproxen sodium — Competitive Intelligence Brief

Comparator: naproxen sodium (Comparator: naproxen sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Rheumatology, Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Rheumatology, Inflammation Small molecule

Target snapshot

Comparator: naproxen sodium (Comparator: naproxen sodium) — Organon and Co. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: naproxen sodium TARGET	Comparator: naproxen sodium	Organon and Co	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Non- effervescent Paracetamol kern	Non- effervescent Paracetamol kern	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	marketed	Analgesic and antipyretic	Cyclooxygenase (COX-1, COX-2)
Diclofenac diethylamine 1.16% gel	Diclofenac diethylamine 1.16% gel	Novartis	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
Loxoprofen sodium tablet	Loxoprofen sodium tablet	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ibuprofen/acetaminophen	Ibuprofen/acetaminophen	Montefiore Medical Center	marketed	Analgesic/antipyretic combination (NSAID + non-NSAID analgesic)	Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen
Aspirin, Acetaminophen, Caffeine pills	Aspirin, Acetaminophen, Caffeine pills	Albert Einstein Healthcare Network	marketed	Analgesic combination product	Cyclooxygenase (COX-1, COX-2); adenosine receptors (caffeine)
Ginger-ibuprofen	Ginger-ibuprofen	Ferrosan AS	marketed	NSAID with herbal adjunct	COX-1, COX-2 (ibuprofen component); multiple inflammatory pathways (ginger component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class